Form 424B5 Verastem, Inc.

Go back to Form 424B5 Verastem, Inc.

Verastem (VSTM) PT Lowered to $7 at B.Riley

July 24, 2024 7:02 AM EDT

B.Riley analyst Kalpit Patel lowered the price target on Verastem (NASDAQ: VSTM) to $7.00 (from $21.00) while maintaining a Buy rating.

The analyst comments "Verastem (VSTMBuy, $7 PT) announced a proposed public offering after market close on 7/23/24. Our enthusiasm for the drugs potential... More